Nine strains produced an enterotoxin demonstrable in newborn mouse assay. Toxin production may be an additional pathogenic mechanism in human yersiniosis.
Yersinia enterocolitica has been increasingly recognised as a human pathogen during the last few years. In adults Y. enterocolitica infections are mainly due to secondary immunological complications, particularly arthritis and erythema nodosum,1-3 which are rare in children. In fact, yersiniosis in small children has been reported to be a relatively mild infection causing diarrhoeal disease not clinically different from other forms of acute gastroenteritis. 4 However, chronic diarrhoea has also been described.5 In older children Y. enterocolitica infection has often been associated with mesenterial lymphadenitis causing an acute, appendicitis-like disease. 6 It has recently been shown that Y. enterocolitica from human sources is invasive for human epithelial cells in vitro.7-9 We have demonstrated polymorphonuclear leucocytes in the stools of patients with Y. enterocolitica infection, and suggested an association between the invasiveness of the pathogen, clinical exudative diarrhoea, and the presence of faecal leucocytes.9
We have now extended our studies on child yersiniosis by analysing clinical features in 40 cases of bacteriologically proved Y. enterocoUltica infection. It Further evidence of the intracellular invasiveness of Y. enterocolitica was obtained by electron microscopical examination (Fig. 2) . After incubation for 7 hours (standard for the invasiveness test) the bacteria were found located in the cytoplasm, either in single vacuoles or in larger groups, probably resulting from rupture and fusion of several vacuoles. A characteristic feature was the presence of swollen, deformed mitochondria. 29 strains were tested for ST-like toxin production using a newborn mouse assay. A positive toxin reaction was seen in 9 instances. All these strains were also invasive in HEp-2 cells. There appeared to be a correlation between toxin production on reculture and time of isolation: most of the strains that failed to produce toxin were old isolates from 1975 which had been stored in nutrient agar at 40C and recultured at 370C for several years (Table  4) . No 'LT-like' enterotoxin activity could be demonstrated in the adrenal cell tests. We were also able to detect this enterotoxin, which resembles the ST enterotoxin of E. coli, by the newborn mouse assay. In our hands, however, only some strains of Y. enterocolitica were enterotoxigenic, and the property of toxin production appeared to be lost in prolonged stock culture. Nevertheless, we do not wish to abandon the concept of enterotoxigenicity of Y. enterocolitica as a possible pathogenic mechanism in yersiniosis. At least two possibilities remain: first, a preformed toxin may act on epithelial cells to induce diarrhoea. This hypothesis should in any case be tested. The second possibility is that toxin production, ST-like or some other, might be an auxiliary pathogenic mechanism acting intracellularly. We propose that the swollen deformed mitochondria found in the epithelial cells invaded by Y. enterocolitica could be attributed to a toxinlike mechanism. It was suggested that a toxic metabolite produced intracellularly by invasive E. coli could destroy epithelial cells and thus lead to colitis and dysentery.27
In conclusion, we suggest that bacterial properties in the pathogenesis of Y. enterocolitica infections include both invasiveness and enterotoxin production. The invasive ability is associated both with the serotype and the biotype. In future studies the toxigenicity should be considered as an additional mechanism, not only in the induction of diarrhoea but also in systemic disease.
In most cases Y. enterocolitica infections in children appear to be self-limiting, despite the invasiveness of the pathogen. Antibiotic treatment is therefore seldom necessary. However, when it is administered on clinical grounds, the results of in vitro antibiotic sensitivity testing should be considered. In our experience, and in that of others,28 sulpha plus trimethoprim (co-trimoxazole) currently appears to be the drug of choice in the treatment of Y. enterocolitica infections both in adults and children.
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